English

• Copper, an essential trace element in the human body, plays a vital role in a range of physiological and pathological processes through its redox activity [1]. In particular, the disruption of Cu(Ⅰ) homeostasis has attracted considerable attention in recent years, owing to the discovery of copper-related molecular mechanisms such as copper accumulation and cuproptosis [2–5]. The dual role of copper dysregulation in tumorigenesis and cancer therapy has emerged as a major focus in oncology research [6–8]. Consequently, the dynamic imaging of Cu(Ⅰ) in living tumor tissues is crucial for elucidating its pathological roles in tumor initiation and progression, and for advancing early diagnostic and therapeutic strategies.

  Fluorescence imaging, with its non-invasive nature, high sensitivity, and real-time visualization capabilities, has become a powerful tool for the dynamic imaging of Cu(Ⅰ) [9–15]. Numerous high-performance fluorescent probes have been developed, enabling precise imaging of Cu(Ⅰ) at the cellular level and in superficial tissues, and offering critical insights into the underlying physiological and pathological mechanisms [16–25]. Notably, the Chang group developed the ratiometric Cu(Ⅰ) probe FCP-1, which facilitated the exploration of the connection between labile intracellular Cu(Ⅰ) pools, glutathione metabolism, and oncogenic transformation [26]. This probe provides a precise tool for investigating the role of Cu(Ⅰ) in cancer progression. The Howell research group employed the CS3 probe to monitor the dynamic fluctuations of Cu(Ⅰ) in a human epithelial cancer cell model, demonstrating its potential as a novel tool for studying Cu-dependent anticancer therapies [27]. However, fluorescence imaging faces inherent limitations such as poor penetration into deep tissues and interference from tissue autofluorescence [28], which hampers its application for high-resolution imaging of Cu(Ⅰ) within live tumors. Addressing this challenge remains a significant objective in the field of molecular probe design Scheme 1.

  Scheme 1

  

  Scheme 1.  Synthesis routes for HCy_Cu1 and HCy_Cu2.

  DownLoad: Full-Size Img PowerPoint

  Photoacoustic (PA) imaging, a non-invasive technique that offers deep tissue penetration and high spatial resolution, has garnered significant attention in biomedical imaging [29–32]. A range of small-molecule PA probes have been developed for imaging of various biological targets within deep living tissues [33,34]. Recent studies have demonstrated the immense potential of small-molecule PA probes for high-resolution, dynamic in vivo imaging of Cu(Ⅰ)/Cu(Ⅱ) [35–40]. For instance, the Chan group reported Cu(Ⅰ)-responsive PA probe, enabling in situ imaging of Cu(Ⅰ) levels in a Wilson's disease mouse model [38]. Our group has further advanced the field by designing a ratiometric PA probe capable of crossing the blood-brain barrier, which, combined with three-dimensional (3D) PA imaging techniques, allowed high-resolution mapping of Cu(Ⅱ) distribution in the brains of Parkinson's disease model mice [39].

  Nevertheless, PA probes continue to face challenges such as long signal acquisition times and relatively low sensitivity compared to fluorescence imaging, limiting their utility for real-time imaging. Integrating the high sensitivity of fluorescence imaging with the deep-tissue, high-resolution capabilities of PA imaging offers a promising strategy to overcome the limitations of single-modality approaches [41–45]. Therefore, the development of Cu(Ⅰ) probes with fluorescence and PA dual-modality imaging capabilities represents a promising solution for the sensitive and high-resolution imaging of Cu(Ⅰ) within living tumors. In this study, we designed and synthesized a small molecular probe, HCy_Cu1, which integrates dual fluorescence and PA imaging functionalities. By introducing a tumor-targeting moiety, we achieved in situ high-resolution imaging of Cu(Ⅰ) within living tumor tissues (Fig. 1).

  Figure 1

  

  Figure 1.  Working principle of HCy_Cu1.

  DownLoad: Full-Size Img PowerPoint

  To realize the dual-modal fluorescence and PA imaging capabilities of the probe, we selected a hemicyanine platform, which offers a balanced performance in both fluorescence and PA properties in the near-infrared (NIR) region [41,46]. An open-chain thia-crown ether, capable of selectively coordinating with Cu(Ⅰ), was introduced at the 6-position of the xanthene unit [18]. Upon coordination with Cu(Ⅰ) via the nitrogen atom at the 6-position and the sulfur atoms of the thia-crown ether, the electron-donating ability of the nitrogen atom is diminished, leading to suppression of the intramolecular charge transfer (ICT) effect. Consequently, the absorption maximum (λ_abs) of the probe undergoes a blue shift, enabling ratiometric PA response to Cu(Ⅰ). In parallel, Cu(Ⅰ) coordination mitigates the fluorescence quenching effect typically induced by the thia-crown ether, resulting in fluorescence enhancement [47]. The changes in ratiometric PA signal and fluorescence intensity upon Cu(Ⅰ) binding collectively endow the probe with tunable dual-modality imaging capabilities.

  Given that neutral cholesterol ester hydrolase 1 (NCEH1) is highly overexpressed in malignant tumors, targeting NCEH1 represents an effective strategy for tumor-specific imaging [48,49]. To this end, we functionalized the 1-position of the indolium moiety with an O-2-isopropylphenyl group, a ligand known for its specific affinity toward NCEH1. Notably, upon binding to NCEH1, the O-2-isopropylphenyl group can undergo a nucleophilic cascade reaction initiated by the hydroxyl group of the active-site serine, leading to the cleavage of the carbonate linkage and covalent anchoring of the probe to NCEH1 [50,51]. This covalent binding mechanism effectively minimizes false-positive signals arising from free probe diffusion. The synthetic routes for the probe is outlined in Scheme 1 and Scheme S1 (Supporting information).

  We initially characterized the photophysical properties of HCy_Cu1 and HCy_Cu2 in ethanol/MOPS buffer (20 mmol/L, pH 7.0, 1:9, v/v). Both probes displayed similar photophysical profiles, with λ_abs at 715 nm and molar extinction coefficients (ε) of 8.6 × 10⁴ L mol⁻¹ cm⁻¹, respectively (Fig. S1 in Supporting information). Upon excitation at 540 nm, maximum emission (λ_em) was observed at 727 nm, with fluorescence quantum yields (Φ_f) of 2.1% and 1.9%. These data suggest that the introduction of the targeting moiety at the indolium position exerts minimal influence on the optical properties of the hemicyanine core.

  Upon addition of Cu(Ⅰ), the absorption of HCy_Cu1 and HCy_Cu2 at 715 and 680 nm diminished, while new peaks emerged at 699 and 665 nm, with intensities increasing proportionally to Cu(Ⅰ) concentration (Fig. 2a and Fig. S2 in Supporting information). The observed hypsochromic-shifts in absorption indicate that Cu(Ⅰ) coordination involves the 6-position nitrogen atom, inhibiting the ICT effect. The appearance of clear isosbestic points at 645, 678, and 707 nm further confirmed a clean, stoichiometric transformation to a single probe+Cu(Ⅰ) complex. The ratio of absorbance at 670 and 730 nm (Abs₆₇₀/₇₃₀) also increased linearly with Cu(Ⅰ) concentration, plateauing at a 1:1 stoichiometry.

  Figure 2

  

  Figure 2.  (a) The absorbance titration spectra of HCy_Cu1 (10 µmol/L) in MOPS buffer. (b) The fluorescence titration spectra of HCy_Cu1 (10 µmol/L) in MOPS buffer. (c) The fluorescence intensity of HCy_Cu1 (10 µmol/L) determined in the presence of Cu(Ⅰ) and other analytes. Data are mean ± SEM (n = 3). (d) SDS-PAGE analysis of NCEH1 with HCy_Cu1–2 were performed with using 10% acrylamide running gel. Fluorescence images of the gels were obtained on a Bio-Rad Chemidoc MP at DyLight 680 channel. The gels were stained with Coomassie brilliant blue (CBB) solution.

  DownLoad: Full-Size Img PowerPoint

  Fluorescence titration studies revealed a concentration-dependent enhancement in emission at 727 nm, with approximately 15-fold and 5-fold increases for HCy_Cu1 and HCy_Cu2, respectively (Fig. 2b and Fig. S3 in Supporting information). This behavior corroborates the 1:1 Cu(Ⅰ) binding model. Notably, unlike the absorption shift, the λ_em remained unchanged after Cu(Ⅰ) binding, likely due to Cu–N bond dissociation at the excited state. Upon binding with Cu(Ⅰ), the Φ_f of HCy_Cu1 and HCy_Cu2 increase to 8.2% and 6.8%, respectively. This enhancement significantly improves their fluorescent properties and contributes to a more balanced performance between fluorescence and PA imaging, thereby making the probes more suitable for dual-modal imaging applications.

  The dissociation constants (K_d) of HCy_Cu1 and HCy_Cu2, determined via a thiourea competitive assay, were found to be 1.68 × 10^–13 and 1.65 × 10^–13 mol/L, respectively (Fig. S4 in Supporting information). Although these values reflect strong Cu(Ⅰ) binding, they remain higher than the K_d values of endogenous Cu(Ⅰ)-binding proteins under physiological conditions (~10^–18 mol/L) [20], suggesting that the probes do not compete with tightly bound Cu(Ⅰ) pools. Therefore, they are well-suited for selectively responding to labile Cu(Ⅰ) under pathological conditions. We further conducted ¹H nuclear magnetic resonance (NMR) titration experiments to provide further evidence for Cu(Ⅰ) binding (Fig. S5 in Supporting information). Gradual addition of Cu(Ⅰ) to HCy_Cu1 in CD₃CN resulted in a progressive downfield shift of the proton signals corresponding to the ethylene groups within the thia-crown ether unit, from 2.02, 2.55, and 2.74 ppm to 2.04, 2.58, and 2.80 ppm upon reaching 1 equiv. of Cu(Ⅰ). Concurrently, the proton signals at the 5- and 7-positions of the xanthene moiety shifted from 6.67 to 6.82 ppm to 6.69 and 6.84 ppm, suggesting that the nitrogen atom at the 6-position was involved in Cu(Ⅰ) coordination. This coordination event led to a decrease in electron density around the 5- and 7-positions, resulting in downfield shifts of their corresponding proton resonances. These NMR titration experiments further confirmed the formation of the probe+Cu(Ⅰ) complex.

  We next assessed probe selectivity by incubation HCy_Cu1 and HCy_Cu2 with a variety of biologically relevant species, including metal ions, anions, reactive oxygen species (ROS), and reactive sulfur species (RSS). Only Cu(Ⅰ) triggered significant changes in Abs₆₇₀/₇₃₀ and fluorescence intensity, demonstrating excellent selectivity even under complex biological conditions (Fig. S6 in Supporting information). Meanwhile, we further examined the response behavior of HCy_Cu1 and HCy_Cu2 to Cu(Ⅰ) in the presence of various biological species. Encouragingly, the results demonstrated that these analytes did not interfere with the response behavior of HCy_Cu1 and HCy_Cu2 to Cu(Ⅰ) (Fig. 2c, Fig. S7 in Supporting information). Moreover, both the absorption and emission spectra of HCy_Cu1 and HCy_Cu2 maintained stability across the physiological pH range and consistent Cu(Ⅰ) responsiveness (Fig. S8 in Supporting information).

  We further evaluated the selective NCEH1-targeting ability of HCy_Cu1 using sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) analysis. As shown in Fig. 2d, HCy_Cu1 exhibited a concentration-dependent fluorescence enhancement at the NCEH1 band, whereas no fluorescence signal was detected for HCy_Cu2. These results demonstrate that HCy_Cu1 possesses superior labeling efficiency compared to HCy_Cu2, underscoring that the introduction of the O-2-isopropylphenyl group significantly enhances the covalent targeting ability of HCy_Cu1 toward NCEH1.

  The highly selective response to Cu(Ⅰ) and the excellent NCEH1 covalent targeting ability of HCy_Cu1 promoted us to further investigate the in vitro and in vivo imaging ability. Before the imaging studies, we first evaluated the cytotoxicity of HCy_Cu1 and HCy_Cu2 in multiple cell lines via standard MTT (3(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assays (Fig. S9 in Supporting information). Both HCy_Cu1 and HCy_Cu2 showed negligible effects on the viability of HepG2, HeLa, 293T and AML12 cell with the concentration up to 20 µmol/L, which affirm the biosafety profile these probes.

  Next, we performed the fluorescent imaging capability of HCy_Cu1 and HCy_Cu2 in HepG2 cells (Fig. 3, Figs. S10 and S11 in Supporting information). Following direct incubation of the probes with cells for 30 min (Ctrl+probe group), weak intracellular fluorescence was observed (Fig. 3a and Fig. S11a), suggesting that both probes possess good membrane permeability. Under identical conditions, cells pretreated with the copper chelator ammonium tetrathiomolybdate (ATTM) (ATTM+probe group) exhibited markedly reduced fluorescence compared to the Ctrl+probe group (Fig. 3b and Fig. S11b), indicating that labile Cu(Ⅰ) was effectively captured by ATTM, thereby preventing its coordination with the probes.

  Figure 3

  

  Figure 3.  Confocal fluorescence imaging of HCy_Cu1 in HepG2 cells. Scale bar: 20 µm. (a) Cells incubated with HCy_Cu1 (10 µmol/L, 30 min) followed by imaging. (b) Cells pretreated with ATTM (500 µmol/L, 30 min), then incubated with HCy_Cu1 (10 µmol/L, 30 min) followed by imaging. (c) Cells pretreated with CuCl₂ (200 µmol/L, 30 min) and then incubated with HCy_Cu1 (10 µmol/L, 30 min) followed by imaging. (d) Cells pretreated with CuCl₂ (200 µmol/L, 30 min), then treated with ATTM (500 µmol/L, 30 min), followed by incubation with HCy_Cu1 (10 µmol/L, 30 min) and imaging. (e) Average fluorescence intensity from Figs. 3a–d. Data are expressed as mean ± SEM (n = 3).

  DownLoad: Full-Size Img PowerPoint

  Notably, cells treated with CuCl₂ and the probes (CuCl₂+probe group) showed a significant fluorescence increase compared to the ATTM+probe group, 3.02-fold for HCy_Cu1 and 4.68-fold for HCy_Cu2 (Figs. 3c and e, Fig. S11c). This fluorescence enhancement was subsequently reversed upon further incubation with ATTM (Fig. 3d and Fig. S11d). Collectively, these results confirm that the fluorescence responses of HCy_Cu1 and HCy_Cu2 in cells are driven by Cu(Ⅰ) levels and demonstrate their capability for dynamic monitoring of intracellular Cu(Ⅰ) fluctuations.

  To further evaluate the in vivo fluorescence imaging performance of the probes, HCy_Cu1 and HCy_Cu2 were administered via tail vein injection into 4T1 tumor-bearing mice. All animals were treated according to the Guide for Care and Use of Laboratory Animals, approved by the Animal Experimentation Ethics Committee of Nanjing University. In the control group receiving saline, no significant fluorescence signals were observed at the tumor sites. Following injection of the probes, the accumulation of HCy_Cu1 and HCy_Cu2 in the tumor regions was monitored over time (Fig. 4a). The results revealed that fluorescence at the tumor site in the HCy_Cu1 group gradually increased, reaching a maximum at 2 h post-injection. In contrast, the fluorescence signal in the HCy_Cu2 group decreased significantly over time, nearly disappearing by 5 h. These observations demonstrate the superior tumor-targeting and accumulation capability of HCy_Cu1 and HCy_Cu2 (Fig. 4b). To avoid possible interference from other biological factors, ATTM was pre-injected into the tumor site 30 min before the tail vein injection of HCy_Cu1. Fluorescence imaging showed that the tumor fluorescence intensity in the ATTM-treated group was markedly lower than that in the untreated HCy_Cu1 group across all time points, confirming that the observed fluorescence signal primarily originated from elevated Cu(Ⅰ) levels in the tumor. These results suggest that HCy_Cu1 enables effective tumor targeting and in vivo imaging of Cu(Ⅰ) dynamics.

  Figure 4

  

  Figure 4.  (a) Fluorescence images of 4T1 tumor-bearing mice with HCy_Cu1, HCy_Cu2 by i.v. injection. (b) Average fluorescence intensity of the tumor region from (a). Data are presented as mean ± SEM (n = 3).

  DownLoad: Full-Size Img PowerPoint

  To evaluate the in vivo PA imaging performance of the probes, HCy_Cu1 and HCy_Cu2 were administered via tail vein injection into 4T1 tumor-bearing mice, followed by 2D PA imaging (Fig. S12a in Supporting information). Over the course of 2 h, a gradual increase in PA signal intensity was observed at the tumor site in the HCy_Cu1 group. In contrast, the HCy_Cu2 group exhibited no significant PA signal enhancement in the tumor region. These results further confirm that the introduction of the O-2-isopropylphenyl group significantly improves tumor retention of HCy_Cu1, consistent with the fluorescence imaging data (Fig. S12b in Supporting information).

  To obtain higher-resolution and more comprehensive spatial distribution data, 3D dual-channel PA imaging was employed. Following tail vein injection of HCy_Cu1, the spatiotemporal distribution of Cu(Ⅰ) within the tumor was monitored over a 2-h period. The PA signal ratio (PA₆₇₀/₇₃₀) steadily increased with time, indicating progressive accumulation of the probe and elevated Cu(Ⅰ) levels (Figs. 5a and b).

  Figure 5

  

  Figure 5.  (a) Ratiometric 3D PA imaging (PA_670/730) of the 4T1 tumor-bearing mice by injection of HCy_Cu1. Scale bar: 3 mm. (b) Average PA_670/730 ratio from (a). (c) Ratiometric 3D PA imaging (PA₆₇₀/₇₃₀) of 4T1 tumor mice with different tumor volumes by injection of HCy_Cu1. Scale bar: 5 mm. (d) Average PA_670/730 ratio from (c).

  DownLoad: Full-Size Img PowerPoint

  As previously reported, tumors exhibit an increased demand for copper due to their high rates of proliferation and angiogenesis. To further examine the relationship between tumor progression and Cu(Ⅰ) accumulation, we conducted dynamic PA imaging in tumors of varying sizes (50–200 mm³) after HCy_Cu1 injection. A positive correlation was observed between tumor volume and PA signal ratio, suggesting that Cu(Ⅰ) levels rise in tandem with tumor growth. These findings demonstrate the capability of HCy_Cu1 to monitor Cu(Ⅰ) dynamics and its potential utility in tumor diagnosis and progression tracking (Figs. 5c and d). In addition, the abdominal vessels are clearly visible in the 730 nm PA channel, with a signal-to-noise ratio (SBR) of 3.91 dB in 3D visualization (Fig. S13a in Supporting information). Therefore, the significant increase in signal ratio and good SBR contribute to clearer tumor imaging as well as more accurate Cu(Ⅰ) distribution information.

  In conclusion, we developed HCy_Cu1, a dual-modality imaging probe for in vivo Cu(Ⅰ) imaging in tumors. This probe exhibits well-balanced NIR fluorescence and PA properties. Upon Cu(Ⅰ) coordination, HCy_Cu1 shows highly selective NIR fluorescence enhancement and a ratiometric PA response, even in complex biological environments. By incorporating a covalent crosslinking group, the probe gains tumor-targeting capability and significantly improved intratumoral retention. In vitro fluorescence imaging in HepG2 cells confirmed the ability of the probe to image intracellular Cu(Ⅰ) dynamics. Furthermore, validation in a 4T1 tumor-bearing mouse model demonstrated the excellent tumor targeting and dual-modality imaging performance of HCy_Cu1 for Cu(Ⅰ). These findings position HCy_Cu1 as a promising tool for Cu(Ⅰ) dual-modal imaging in tumors, offering valuable insights into the role of Cu(Ⅰ) played in tumor progression and potentially aiding in the development of new cancer diagnostic and therapeutic strategies.

  Declaration of competing interest

  The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

  CRediT authorship contribution statement

  Hang Liu: Writing – original draft, Methodology, Investigation, Formal analysis, Data curation. Qian Sun: Methodology, Investigation, Formal analysis, Data curation. Mengxi Dong: Methodology, Investigation. Xiaoqing Wang: Writing – review & editing, Supervision, Funding acquisition, Conceptualization. Zhipeng Liu: Writing – review & editing, Supervision, Funding acquisition, Conceptualization.

  Acknowledgments

  We thank the National Natural Science Foundation of China (Nos. 22371124 and 22377057), and Natural Science Foundation of Jiangsu Province (Nos. BK20231298 and BK20221333) for financial support.

  Supplementary materials

  Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.cclet.2025.111655.

  
  
• 1. [1]

     S.J. Lippard, J.M. Berg, Principles of Bioinorganic Chemistry, University Science Books, Mill Valley, 1994.

  2. [2]

     S. Solier, S. Müller, T. Cañeque, et al., Nature 617 (2023) 386–394. doi: 10.1038/s41586-023-06017-4

  3. [3]

     E. Gaggelli, H. Kozlowski, D. Valensin, G. Valensin, Chem. Rev. 106 (2006) 1995–2044. doi: 10.1021/cr040410w

  4. [4]

     V. Desai, S.G. Kaler, Am. J. Clin. Nutr. 88 (2008) 855S–858S. doi: 10.1093/ajcn/88.3.855S

  5. [5]

     B.E. Kim, T. Nevitt, D.J. Thiele, Nat. Chem. Biol. 4 (2008) 176–185. doi: 10.1038/nchembio.72

  6. [6]

     Y. Yang, M. Li, G. Chen, et al., Coord. Chem. Rev. 495 (2023) 215395. doi: 10.1016/j.ccr.2023.215395

  7. [7]

     D.L. Tang, G. Kroemer, R. Kang, Nat. Rev. Clin. Oncol. 21 (2024) 370–388. doi: 10.1038/s41571-024-00876-0

  8. [8]

     E.J. Ge, A.I. Bush, A. Casini, et al., Nat. Rev. Cancer 22 (2022) 102–113. doi: 10.1038/s41568-021-00417-2

  9. [9]

     J.J.A. Cotruvo, A.T. Aron, K.M. Ramos-Torres, C.J. Chang, Chem. Soc. Rev. 44 (2015) 4400–4414. doi: 10.1039/C4CS00346B

  10. [10]

      C.J. Fahrni, Curr. Opin. Chem. Biol. 17 (2013) 656–662. doi: 10.1016/j.cbpa.2013.05.019

  11. [11]

      M.C. Heffern, H.M. Park, H.Y. Au-Yeung, et al., Proc. Natl. Acad. Sci. U. S. A. 113 (2016) 14219–14224. doi: 10.1073/pnas.1613628113

  12. [12]

      Y. Chen, H. Jiang, T. Hao, Chem. Biomed. Imaging 1 (2023) 590–619. doi: 10.1021/cbmi.3c00029

  13. [13]

      W. Mao, P. Dong, W. Du, H. Wu, Chem. Biomed. Imaging 3 (2025) 1–4. doi: 10.1021/cbmi.4c00095

  14. [14]

      A. Sharma, P. Verwilst, M. Li, Chem. Rev. 124 (2024) 2699–2804. doi: 10.1021/acs.chemrev.3c00778

  15. [15]

      A. Yu, X. He, T. Shen, Chem. Soc. Rev. 54 (2025) 2984–3016. doi: 10.1039/d3cs00520h

  16. [16]

      R. Cheng, Y. Nishikawa, T. Wagatsuma, et al., ACS Chem. Biol. 19 (2024) 1222–1228. doi: 10.1021/acschembio.4c00011

  17. [17]

      M. Priessner, P.A. Summers, B.W. Lewis, et al., Angew. Chem. Int. Ed. 60 (2021) 23148–23153. doi: 10.1002/anie.202109349

  18. [18]

      H.X. Xu, S.K. Yao, Y.C. Chen, et al., Inorg. Chem. 60 (2021) 18567–18574. doi: 10.1021/acs.inorgchem.1c01779

  19. [19]

      S. Lee, C.Y. Chung, P. Liu, et al., J. Am. Chem. Soc. 142 (2020) 14993–15003. doi: 10.1021/jacs.0c05727

  20. [20]

      M.T. Morgan, D. Bourassa, S. Harankhedkar, et al., Proc. Natl. Acad. Sci. U. S. A. 116 (2019) 12167–12172. doi: 10.1073/pnas.1900172116

  21. [21]

      T. Xiao, C.M. Ackerman, E.C. Carroll, et al., Chem. Biol. 14 (2018) 655–663. doi: 10.1038/s41589-018-0062-z

  22. [22]

      C. Shen, J.L. Kolanowski, C.M.N. Tran, et al., Metallomics 8 (2016) 915–919. doi: 10.1039/C6MT00083E

  23. [23]

      J. Liu, J. Karpus, S.V. Wegner, P.R. Chen, C. He, J. Am. Chem. Soc. 135 (2013) 3144–3149. doi: 10.1021/ja3106779

  24. [24]

      T. Hirayama, G.C. Van de Bittner, L.W. Gray, S. Lutsenko, C.J. Chang, Proc. Natl. Acad. Sci. U. S. A. 109 (2012) 2228–2233. doi: 10.1073/pnas.1113729109

  25. [25]

      S.C. Dodani, D.W. Domaille, C.I. Nam, et al., Proc. Natl. Acad. Sci. U. S. A. 108 (2011) 5980–5985. doi: 10.1073/pnas.1009932108

  26. [26]

      C.Y. Chung, J.M. Posimo, S. Lee, et al., Proc. Natl. Acad. Sci. U. S. A. 116 (2019) 18285–18294. doi: 10.1073/pnas.1904610116

  27. [27]

      C.P. Huang, M. Fofana, J. Chan, C.J. Chang, S.B. Howell, Metallomics 6 (2014) 654. doi: 10.1039/c3mt00331k

  28. [28]

      C. Li, G. Chen, Y. Zhang, F. Wu, Q. Wang, J. Am. Chem. Soc. 142 (2020) 14789–14804. doi: 10.1021/jacs.0c07022

  29. [29]

      L.V. Wang, S. Hu, Science 335 (2012) 1458–1462. doi: 10.1126/science.1216210

  30. [30]

      K. Haedicke, L. Agemy, M. Omar, et al., Nat. Biomed. Eng. 4 (2020) 286–297. doi: 10.1038/s41551-020-0527-8

  31. [31]

      S. Na, J.J. Russin, L. Lin, et al., Nat. Biomed. Eng. 6 (2022) 584–592.

  32. [32]

      X. Zhang, Y. Wu, L. Chen, J. Song, H. Yang, Chem. Biomed. Imaging 1 (2023) 99–109. doi: 10.1021/cbmi.3c00009

  33. [33]

      Y. Liu, L. Teng, B. Yin, et al., Chem. Rev. 122 (2022) 6850–6918. doi: 10.1021/acs.chemrev.1c00875

  34. [34]

      K. Song, H. Gao, X. Wang, Z. Liu, ChemPhotoChem 9 (2025) e202400335. doi: 10.1002/cptc.202400335

  35. [35]

      S. Wang, Z. Sheng, Z. Yang, et al., Angew. Chem. Int. Ed. 58 (2019) 12415–12419. doi: 10.1002/anie.201904047

  36. [36]

      H. Li, P. Zhang, L.P. Smaga, R.A. Hoffman, J. Chan, J. Am. Chem. Soc. 137 (2015) 15628–15631. doi: 10.1021/jacs.5b10504

  37. [37]

      L. Zeng, G. Ma, H. Xu, et al., Small 15 (2019) e1803866. doi: 10.1002/smll.201803866

  38. [38]

      M.Y. Lucero, Y.Q. Tang, C.J. Zhang, et al., Proc. Nat. Acad. Sci. U. S. A. 118 (2021) e2106943118. doi: 10.1073/pnas.2106943118

  39. [39]

      Z. Jiang, C. Zhang, X. Wang, et al., Angew. Chem. Int. Ed. 63 (2024) e202318340. doi: 10.1002/anie.202318340

  40. [40]

      Q. Sun, H. Liu, Y. Yang, et al., Chem. Biomed. Imaging 3 (2025) 260–266. doi: 10.1021/cbmi.4c00115

  41. [41]

      S.P. Zhang, H. Chen, L.P. Wang, et al., Angew. Chem. Int. Ed. 61 (2022) e202107076. doi: 10.1002/anie.202107076

  42. [42]

      C. Zhang, Z. Qiu, L. Zhang, et al., Anal. Chem. 94 (2022) 6251–6260. doi: 10.1021/acs.analchem.2c00041

  43. [43]

      S.Y. Ong, C.Y. Zhang, X. Dong, S.Q. Yao, Angew. Chem. Int. Ed. 60 (2021) 17797–17809. doi: 10.1002/anie.202101964

  44. [44]

      S. Yao, Z. Wu, Y. Zhang, et al., CCS Chemistry 7 (2025) 596–609. doi: 10.31635/ccschem.024.202404092

  45. [45]

      Y. Zhang, S. Lei, Y. Pan, et al., Chin. Chem. Lett. 37 (2026) 110977. doi: 10.1016/j.cclet.2025.110977

  46. [46]

      S. Yao, Y. Chen, W. Ding, et al., Chem. Sci. 14 (2023) 1234–1243. doi: 10.1039/d2sc05982g

  47. [47]

      L. Zeng, E.W. Miller, A. Pralle, E.Y. Isacoff, C.J. Chang, J. Am. Chem. Soc. 128 (2006) 10–11. doi: 10.1021/ja055064u

  48. [48]

      J.W. Chang, D.K. Nomura, B.F. Cravatt, Chem. Biol. 18 (2011) 476–484. doi: 10.1016/j.chembiol.2011.02.008

  49. [49]

      D.A. Bachovchin, T. Ji, W. Li, et al., Proc. Nat. Acad. Sci. U. S. A. 107 (2010) 20941–20946. doi: 10.1073/pnas.1011663107

  50. [50]

      J.W. Chang, M. Bhuiyan, H.M. Tsai, et al., Angew. Chem. Int. Ed. 59 (2020) 15161–15165. doi: 10.1002/anie.202004762

  51. [51]

      J.W. Chang, R.E. Moellering, B.F. Cravatt, Angew. Chem. Int. Ed. 51 (2011) 966–970.

• 

  Scheme 1  Synthesis routes for HCy_Cu1 and HCy_Cu2.

  下载: 全尺寸图片 幻灯片
  

  Figure 1  Working principle of HCy_Cu1.

  下载: 全尺寸图片 幻灯片
  

  Figure 2  (a) The absorbance titration spectra of HCy_Cu1 (10 µmol/L) in MOPS buffer. (b) The fluorescence titration spectra of HCy_Cu1 (10 µmol/L) in MOPS buffer. (c) The fluorescence intensity of HCy_Cu1 (10 µmol/L) determined in the presence of Cu(Ⅰ) and other analytes. Data are mean ± SEM (n = 3). (d) SDS-PAGE analysis of NCEH1 with HCy_Cu1–2 were performed with using 10% acrylamide running gel. Fluorescence images of the gels were obtained on a Bio-Rad Chemidoc MP at DyLight 680 channel. The gels were stained with Coomassie brilliant blue (CBB) solution.

  下载: 全尺寸图片 幻灯片
  

  Figure 3  Confocal fluorescence imaging of HCy_Cu1 in HepG2 cells. Scale bar: 20 µm. (a) Cells incubated with HCy_Cu1 (10 µmol/L, 30 min) followed by imaging. (b) Cells pretreated with ATTM (500 µmol/L, 30 min), then incubated with HCy_Cu1 (10 µmol/L, 30 min) followed by imaging. (c) Cells pretreated with CuCl₂ (200 µmol/L, 30 min) and then incubated with HCy_Cu1 (10 µmol/L, 30 min) followed by imaging. (d) Cells pretreated with CuCl₂ (200 µmol/L, 30 min), then treated with ATTM (500 µmol/L, 30 min), followed by incubation with HCy_Cu1 (10 µmol/L, 30 min) and imaging. (e) Average fluorescence intensity from Figs. 3a–d. Data are expressed as mean ± SEM (n = 3).

  下载: 全尺寸图片 幻灯片
  

  Figure 4  (a) Fluorescence images of 4T1 tumor-bearing mice with HCy_Cu1, HCy_Cu2 by i.v. injection. (b) Average fluorescence intensity of the tumor region from (a). Data are presented as mean ± SEM (n = 3).

  下载: 全尺寸图片 幻灯片
  

  Figure 5  (a) Ratiometric 3D PA imaging (PA_670/730) of the 4T1 tumor-bearing mice by injection of HCy_Cu1. Scale bar: 3 mm. (b) Average PA_670/730 ratio from (a). (c) Ratiometric 3D PA imaging (PA₆₇₀/₇₃₀) of 4T1 tumor mice with different tumor volumes by injection of HCy_Cu1. Scale bar: 5 mm. (d) Average PA_670/730 ratio from (c).

  下载: 全尺寸图片 幻灯片
•